[Allogenic transplantation of bone marrow in childhood]. 1995

J Starý, and P Kobylka, and P Kavan, and V Komrska, and Z Syrůcková, and V Vávra, and P Sedlácek, and A Hrubá, and J Frýdl, and J Mrácek
II. Dĕtská klinika FN Motol, Praha.

BACKGROUND Bone marrow transplantation has become the therapeutic method in some forms of malignant haemotopoietic diseases, malignant tumours, inborn errors of metabolism and immunodeficiency states. The objective of the presented work is the analysis of 40 allogenic bone marrow transplantations in children made in 1989-1994. RESULTS Bone marrow transplantation was made in 40 children (26 boys and 14 girls), mean age 10.5 years (range 1.5-17.5 years). Indications were acute lymphoblastic leukaemia in 11, acute myeloid leukaemia in 10, chronic myeloid leukaemia in 6, myelodysplastic syndrome in 2, aplastic anaemia and Fanconi's anaemia in 7, non-Hodgkin lymphoma in 2 and inborn errors in 2 children. The donor was in 33 patients in HLA identical sibling and in seven instances a monozygotic twin, HLA non-identical sibling or relative or unrelated matched donor. Bone marrow engraftment was achieved in 35 (87.5%) patients, in one instance the bone marrow was rejected (2.5%) and in four patients (10%) early death occurred before the bone marrow engraftment. On Aug. 15, 1995 20 patients (50%) survived, a relapse developed in 7 (17.5%) and 13 patients died in conjunction with the transplantation (32.5%). The most frequent cause of death were infectious complications (9 children) either in conjunction with the development of graft versus host reaction (6x) or without signs of this reaction (3x). As a prophylaxis of graft versus host disease 24x Cyclosporine A with corticosteroids was used, 16x with methotrexate. A chronic graft versus host disease developed in 6 of 28 children surviving 100 days after transplantation. The greatest problem are infectious (bacterial and mycotic) complications in the phase of bone marrow aplasia before engraftment of the transplanted bone marrow or in conjunction with a graft versus host reaction which cannot be completely avoided by preventive measures. CONCLUSIONS Bone marrow transplantation is also in children an effective therapeutic method of some forms of malignant haematopoietic diseases, malignant tumours and immunodeficiency states. The correct indication, suitable donor, preventive measures against the graft versus host reaction and protection against infectious complications are essential for the success of this pretentious treatment.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D014184 Transplantation, Homologous Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals. Transplantation, Allogeneic,Allogeneic Grafting,Allogeneic Transplantation,Allografting,Homografting,Homologous Transplantation,Grafting, Allogeneic
D016026 Bone Marrow Transplantation The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION. Bone Marrow Cell Transplantation,Grafting, Bone Marrow,Transplantation, Bone Marrow,Transplantation, Bone Marrow Cell,Bone Marrow Grafting

Related Publications

J Starý, and P Kobylka, and P Kavan, and V Komrska, and Z Syrůcková, and V Vávra, and P Sedlácek, and A Hrubá, and J Frýdl, and J Mrácek
January 2003, Casopis lekaru ceskych,
J Starý, and P Kobylka, and P Kavan, and V Komrska, and Z Syrůcková, and V Vávra, and P Sedlácek, and A Hrubá, and J Frýdl, and J Mrácek
July 1995, Rinsho byori. The Japanese journal of clinical pathology,
J Starý, and P Kobylka, and P Kavan, and V Komrska, and Z Syrůcková, and V Vávra, and P Sedlácek, and A Hrubá, and J Frýdl, and J Mrácek
January 1975, Hamatologie und Bluttransfusion,
J Starý, and P Kobylka, and P Kavan, and V Komrska, and Z Syrůcková, and V Vávra, and P Sedlácek, and A Hrubá, and J Frýdl, and J Mrácek
July 1988, Revista clinica espanola,
J Starý, and P Kobylka, and P Kavan, and V Komrska, and Z Syrůcková, and V Vávra, and P Sedlácek, and A Hrubá, and J Frýdl, and J Mrácek
November 1997, Anales espanoles de pediatria,
J Starý, and P Kobylka, and P Kavan, and V Komrska, and Z Syrůcková, and V Vávra, and P Sedlácek, and A Hrubá, and J Frýdl, and J Mrácek
January 1991, Wiener medizinische Wochenschrift (1946),
J Starý, and P Kobylka, and P Kavan, and V Komrska, and Z Syrůcková, and V Vávra, and P Sedlácek, and A Hrubá, and J Frýdl, and J Mrácek
August 1982, Biulleten' eksperimental'noi biologii i meditsiny,
J Starý, and P Kobylka, and P Kavan, and V Komrska, and Z Syrůcková, and V Vávra, and P Sedlácek, and A Hrubá, and J Frýdl, and J Mrácek
January 2002, European journal of ophthalmology,
J Starý, and P Kobylka, and P Kavan, and V Komrska, and Z Syrůcková, and V Vávra, and P Sedlácek, and A Hrubá, and J Frýdl, and J Mrácek
January 2005, Gut,
J Starý, and P Kobylka, and P Kavan, and V Komrska, and Z Syrůcková, and V Vávra, and P Sedlácek, and A Hrubá, and J Frýdl, and J Mrácek
March 1996, Hematological oncology,
Copied contents to your clipboard!